This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1bvl

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1bvl.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1bvl.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1bvl| PDB=1bvl | SCENE= }}
{{STRUCTURE_1bvl| PDB=1bvl | SCENE= }}
-
'''HUMANIZED ANTI-LYSOZYME FV'''
+
===HUMANIZED ANTI-LYSOZYME FV===
-
==Overview==
+
<!--
-
We have determined the crystal structure of the Fv fragment of a humanized anti-hen eggwhite lysozyme Ab (HuLys). This molecule is a composite of known structures: complementarity-determining regions (CDRs) were from the mouse anti-lysozyme Ab D1.3, heavy chain framework regions were from the human myeloma protein NEW, and the light chain framework regions were consensus sequences similar to the Bence Jones protein REI. HuLys crystallized in space group P4(3)2(1)2, with two Fv molecules in the crystallographic asymmetric unit. The structure was solved by molecular replacement, using a composite of the parent structures as a search model. The resolution of the structure was 2.87 A, with an R factor of 22%. There were several unanticipated structural similarities and differences between HuLys and the mouse and human structures. The framework regions of HuLys were as close or closer in conformation to D1.3 than to the NEW or REI protein, despite overwhelming sequence identity with the human framework regions. The effect was most pronounced at the CDR-framework junction, showing that the CDRs can induce structural changes in framework residues, having the net effect in HuLys of reconforming the framework into a conformation more like D1.3. In the combining site, the grafted CDRs retained conformational equilibria seen in D1.3, demonstrating that humanizing can be applied to Abs that bind Ags through isomeric equilibrium or induced fit mechanisms. In addition, HuLys showed systematic differences from D1.3 that resembled domain rotations reported for other Abs. However, the V(H)-V(L) interface itself was unaffected, and the apparent movement was actually caused by rearrangements distant from this surface.
+
The line below this paragraph, {{ABSTRACT_PUBMED_9036965}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 9036965 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_9036965}}
==About this Structure==
==About this Structure==
Line 27: Line 31:
[[Category: Fv]]
[[Category: Fv]]
[[Category: Humanized antibody]]
[[Category: Humanized antibody]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 12:00:25 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jun 30 19:47:12 2008''

Revision as of 16:47, 30 June 2008

Image:1bvl.png

Template:STRUCTURE 1bvl

HUMANIZED ANTI-LYSOZYME FV

Template:ABSTRACT PUBMED 9036965

About this Structure

1BVL is a Protein complex structure of sequences from Homo sapiens and mus musculus. Full crystallographic information is available from OCA.

Reference

Structural consequences of humanizing an antibody., Holmes MA, Foote J, J Immunol. 1997 Mar 1;158(5):2192-201. PMID:9036965

Page seeded by OCA on Mon Jun 30 19:47:12 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1bvl"
Personal tools